See where your brand stands in AI answers

Free. About a minute. No sign-up.

Know where you stand. Find your next opportunity.

Products

Brands
Markets
Topics
Work with us
Pricing

Resources

Research
Methodology
Blog
MCP
For AI

Compare

Parse vs Profound
Parse vs Peec AI
Parse vs AthenaHQ
Parse vs Scrunch
Parse vs Otterly.AI
All comparisons

Company

About
Dimitry Apollonsky
Contact us
Corrections

Pricing

What AI says about Avidity Biosciences | Parse

Track Avidity Biosciences. Free.

Track Avidity Biosciences

Brands

Brands

Avidity Biosciences

What AI says about Avidity Biosciences

Track Avidity Biosciences free

aviditybiosciences.com

AI summary

Avidity Biosciences is a biotechnology company developing Antibody Oligonucleotide Conjugates to treat muscle diseases by targeting the root genetic causes.

AI named Avidity Biosciences from November 2025 to June 2026.

Avidity Biosciences in AI’s own words

Question: What are the latest affordable advancements in biopharma for treating rare diseases?

ChatGPT SearchJun 14, 2026

Avidity Biosciences receives FDA breakthrough therapy designation for delpacibart zotadirsen (del-zota) for the treatment of DMD in people with mutations amenable to exon 44 skipping

Ask ChatGPT yourself (opens in a new tab)

Track Avidity Biosciences: see where AI mentions it and what to do next.

Track Avidity Biosciences

Competitors

AI named Avidity Biosciences most often alongside Aldevron, Ascidian Therapeutics, and Beam

See where AI mentions Avidity Biosciences

Track Avidity Biosciences

See where AI mentions Avidity Biosciences

Track Avidity Biosciences

Aldevron
Ascidian Therapeutics
Beam
Beam Therapeutics
Children's Hospital of Philadelphia

Sources AI cites

None of these answers cited aviditybiosciences.com. AI leaned on reuters.com, biopharmadive.com, and biospace.com.

aviditybiosciences.com 0%Other sites 100%

reuters.com (opens in a new tab)23%
biopharmadive.com (opens in a new tab)15%
biospace.com (opens in a new tab)8%
crisprtx.gcs-web.com (opens in a new tab)8%
fda.gov (opens in a new tab)8%

Questions and answers

What are the latest affordable advancements in biopharma for treating rare diseases?
Excerpts where Avidity Biosciences appeared in the AI's answer
ChatGPT SearchJun 14, 2026, ChatGPT Search
Avidity Biosciences receives FDA breakthrough therapy designation for delpacibart zotadirsen (del-zota) for the treatment of DMD in people with mutations amenable to exon 44 skipping